Clustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent Apoptosis-Reference-Cited by-同舟云学术

Clustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent Apoptosis

Published:2000-04 Issue:2 Volume:26 Page:133-143
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Hofmeister Joseph K,Cooney Damon,Coggeshall K.Mark

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference36 articles.

1. Monoclonal antibody-based therapies for hematologic malignancies;Multani;J. Clin. Oncol.,1998

2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program;McLaughlin;J. Clin. Oncol.,1998

3. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies;Shan;Blood,1998

4. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC–C2B8 anti-CD20 monoclonal antibody;Taji;Jpn. J. Cancer Res.,1998

5. CD20: A regulator of cell-cycle progression of B lymphocytes;Tedder;Immunol. Today,1994

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

4. Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting;Frontiers in Immunology;2023-09-28

5. Multi-targeted immunotherapeutics to treat B cell malignancies;Journal of Controlled Release;2023-06